Sitagliptin (Januvia™) is a new oral agent approved by the US FDA to treat Type 2 diabetes. This is the first approved agent in a new class of antihyperglycemics, dipeptidyl peptidase (DPP)-4 ...
Researchers from the US have shown that combination therapy with sitagliptin and metformin results in a substantial and additive glycemic improvement in patients with type 2 diabetes. Sitagliptin ...
No changes were observed in IGF-1 or IGF-binding protein-3 (nonsignificant for between-group comparisons). [15] Data on safety and efficacy are not available for sitagliptin use in children ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback